Hualan Biological Engineering: Higher VAT and weaker vaccine demand drove steep Q3 declines despite 15% plasma-collection growth

What happened

Hualan Biological Engineering's third-quarter revenue fell 35.75% from a year earlier and attributable net profit fell 82.41%. Year-to-date revenue and profit declined 23.58% and 45.11%. Higher value-added tax, policy-driven demand and pricing pressure hurt results, while plasma collection volume rose 15%.

Confirmed

Global impact / market context

A value-added tax is a tax charged at each stage of sale, so a higher rate raises costs the company may not fully pass on. Combined with weaker demand and lower prices, this squeezes profit per sale even as plasma collection grows.

Analyst inference

The results show a vaccine maker facing both tax costs and softer demand, so profit falls much faster than revenue. Investors may question whether the 15% plasma-collection growth can offset pricing pressure and turn into revenue in later quarters.

Analyst inference

What to watch

1. Watch whether the higher value-added tax rate remains in place in coming quarters. Confirmed
2. Watch for any company update on pricing or policy-driven demand for its vaccine products. Proposed
3. Track whether the 15% plasma-collection growth converts into sales and profit, since collection gains alone did not offset the declines. Analyst inference

Evidence

• Original source link unavailable